CA3139063A1 - Kcnt1 inhibitors and methods of use - Google Patents
Kcnt1 inhibitors and methods of use Download PDFInfo
- Publication number
- CA3139063A1 CA3139063A1 CA3139063A CA3139063A CA3139063A1 CA 3139063 A1 CA3139063 A1 CA 3139063A1 CA 3139063 A CA3139063 A CA 3139063A CA 3139063 A CA3139063 A CA 3139063A CA 3139063 A1 CA3139063 A1 CA 3139063A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- 6alkyl
- group
- phenyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842849P | 2019-05-03 | 2019-05-03 | |
| US62/842,849 | 2019-05-03 | ||
| US202062982864P | 2020-02-28 | 2020-02-28 | |
| US62/982,864 | 2020-02-28 | ||
| PCT/US2020/031046 WO2020227101A1 (en) | 2019-05-03 | 2020-05-01 | Kcnt1 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3139063A1 true CA3139063A1 (en) | 2020-11-12 |
Family
ID=73051241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3139063A Pending CA3139063A1 (en) | 2019-05-03 | 2020-05-01 | Kcnt1 inhibitors and methods of use |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220259193A1 (https=) |
| EP (1) | EP3962481A4 (https=) |
| JP (2) | JP7667573B2 (https=) |
| KR (1) | KR20220016086A (https=) |
| CN (2) | CN114269340A (https=) |
| AU (1) | AU2020267356B2 (https=) |
| BR (1) | BR112021022067A2 (https=) |
| CA (1) | CA3139063A1 (https=) |
| CL (2) | CL2021002877A1 (https=) |
| CO (1) | CO2021016471A2 (https=) |
| EC (1) | ECSP21087884A (https=) |
| IL (1) | IL287768A (https=) |
| MX (1) | MX2021013421A (https=) |
| PE (1) | PE20220016A1 (https=) |
| SA (1) | SA521430751B1 (https=) |
| SG (1) | SG11202112158YA (https=) |
| WO (1) | WO2020227101A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12590083B2 (en) | 2019-01-25 | 2026-03-31 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy |
| KR20250172745A (ko) * | 2019-05-03 | 2025-12-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| JP7699836B2 (ja) * | 2020-02-28 | 2025-06-30 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤、および使用方法 |
| EP4210824A1 (en) * | 2020-09-09 | 2023-07-19 | University of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| TW202227424A (zh) * | 2020-11-27 | 2022-07-16 | 大陸商瑞石生物醫藥有限公司 | 芳基或雜芳基取代５員芳雜環化合物及其用途 |
| WO2022140547A2 (en) * | 2020-12-22 | 2022-06-30 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| EP4329735B1 (en) * | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2023211850A1 (en) * | 2022-04-25 | 2023-11-02 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
| US20250360117A1 (en) * | 2022-06-08 | 2025-11-27 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
| CN116813505B (zh) * | 2023-06-29 | 2025-09-02 | 爱斯特（成都）生物制药股份有限公司 | 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法 |
| WO2025117662A1 (en) * | 2023-11-29 | 2025-06-05 | Actio Biosciences, Inc. | Heterocyclic compounds useful as kcnt1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| TW200301698A (en) * | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| JP2005060255A (ja) * | 2003-08-20 | 2005-03-10 | Nippon Nohyaku Co Ltd | カルボキサミド類及びこれを有効成分とする有害生物防除剤 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| ES2895174T3 (es) | 2014-09-29 | 2022-02-17 | Scripps Research Inst | Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares |
| EP3275440B1 (en) * | 2015-03-25 | 2022-05-04 | National Center for Geriatrics and Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
| JPWO2017170826A1 (ja) * | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−１受容体作用増強活性を有する化合物 |
| WO2018187480A1 (en) * | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP7699836B2 (ja) * | 2020-02-28 | 2025-06-30 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤、および使用方法 |
| KR20230005168A (ko) * | 2020-03-23 | 2023-01-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| CA3188825A1 (en) * | 2020-07-06 | 2022-01-13 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US11773088B2 (en) * | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| WO2022140547A2 (en) * | 2020-12-22 | 2022-06-30 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| EP4329735B1 (en) * | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
-
2020
- 2020-05-01 KR KR1020217039174A patent/KR20220016086A/ko not_active Ceased
- 2020-05-01 BR BR112021022067A patent/BR112021022067A2/pt unknown
- 2020-05-01 AU AU2020267356A patent/AU2020267356B2/en active Active
- 2020-05-01 SG SG11202112158YA patent/SG11202112158YA/en unknown
- 2020-05-01 WO PCT/US2020/031046 patent/WO2020227101A1/en not_active Ceased
- 2020-05-01 CN CN202080047961.1A patent/CN114269340A/zh active Pending
- 2020-05-01 MX MX2021013421A patent/MX2021013421A/es unknown
- 2020-05-01 CA CA3139063A patent/CA3139063A1/en active Pending
- 2020-05-01 US US17/607,802 patent/US20220259193A1/en active Pending
- 2020-05-01 PE PE2021001828A patent/PE20220016A1/es unknown
- 2020-05-01 CN CN202510784123.7A patent/CN120817941A/zh active Pending
- 2020-05-01 EP EP20801870.5A patent/EP3962481A4/en active Pending
- 2020-05-01 JP JP2021564995A patent/JP7667573B2/ja active Active
-
2021
- 2021-11-01 IL IL287768A patent/IL287768A/en unknown
- 2021-11-02 CL CL2021002877A patent/CL2021002877A1/es unknown
- 2021-11-03 SA SA521430751A patent/SA521430751B1/ar unknown
- 2021-12-02 CO CONC2021/0016471A patent/CO2021016471A2/es unknown
- 2021-12-03 EC ECSENADI202187884A patent/ECSP21087884A/es unknown
-
2024
- 2024-07-08 CL CL2024002067A patent/CL2024002067A1/es unknown
-
2025
- 2025-04-04 JP JP2025062493A patent/JP2025102975A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025102975A (ja) | 2025-07-08 |
| CN114269340A (zh) | 2022-04-01 |
| EP3962481A1 (en) | 2022-03-09 |
| CL2024002067A1 (es) | 2024-12-13 |
| ECSP21087884A (es) | 2022-01-31 |
| KR20220016086A (ko) | 2022-02-08 |
| EP3962481A4 (en) | 2023-03-22 |
| AU2020267356A1 (en) | 2022-01-06 |
| CO2021016471A2 (es) | 2022-04-08 |
| MX2021013421A (es) | 2022-02-11 |
| JP7667573B2 (ja) | 2025-04-23 |
| SG11202112158YA (en) | 2021-12-30 |
| IL287768A (en) | 2022-01-01 |
| CN120817941A (zh) | 2025-10-21 |
| WO2020227101A1 (en) | 2020-11-12 |
| JP2022531388A (ja) | 2022-07-06 |
| PE20220016A1 (es) | 2022-01-11 |
| BR112021022067A2 (pt) | 2022-05-17 |
| CL2021002877A1 (es) | 2022-08-12 |
| SA521430751B1 (ar) | 2024-02-01 |
| AU2020267356B2 (en) | 2025-04-24 |
| US20220259193A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3139063A1 (en) | Kcnt1 inhibitors and methods of use | |
| EP3580220B1 (en) | Aminotriazolopyridines as kinase inhibitors | |
| TW201734001A (zh) | ＲＯＲ－γ調節劑 | |
| CN105517993B (zh) | 芳基酰胺激酶抑制剂 | |
| RS59007B1 (sr) | Dihidropirolopiridinski inhibitori ror-gama | |
| JP7824664B2 (ja) | Ｋｃｎｔ１阻害剤及び使用方法 | |
| TW201443046A (zh) | 噻二唑類似物及治療ｓｍｎ缺乏相關症狀之方法 | |
| AU2018361249A1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| EP4110317B1 (en) | Kcnt1 inhibitors and methods of use | |
| US20240043415A1 (en) | Kcnt1 inhibitors and methods of use | |
| WO2021202781A1 (en) | N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonists | |
| AU2021227935B2 (en) | KCNT1 inhibitors and methods of use | |
| HK40069627A (en) | Modulators of ror-gamma | |
| WO2023122152A1 (en) | Kcnt1 inhibitors and methods of use | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ | |
| BR112016017738B1 (pt) | "inibidores de di-hidropirrolopiridina de ror-gama e composição farmacêutica | |
| HK40001214B (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| NZ616395A (en) | Androgen receptor modulating carboxamides for the treatment of cancer | |
| NZ616395B2 (en) | Androgen receptor modulating carboxamides for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240426 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250919 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260326 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260409 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260409 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260409 |